RT Journal Article
SR Electronic
T1 Beneficial immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in young boys with Duchenne muscular dystrophy: Results of an open-label, prospective, exploratory clinical study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.13.21267706
DO 10.1101/2021.12.13.21267706
A1 Raghavan, Kadalraja
A1 Dedeepiya, Vidyasagar Devaprasad
A1 Srinivasan, Subramaniam
A1 Pushkala, Subramanian
A1 Subramanian, Sudhakar
A1 Ikewaki, Nobunao
A1 Iwasaki, Masaru
A1 Senthilkumar, Rajappa
A1 Preethy, Senthilkumar
A1 Abraham, Samuel JK
YR 2022
UL http://medrxiv.org/content/early/2022/09/01/2021.12.13.21267706.abstract
AB Background This trial is to evaluate the effects of supplementation of Aureobasidium pullulans-N-163 strain produced 1,3-1,-6 beta glucan in young patients with Duchenne muscular dystrophy (DMD).Methods Twenty-seven male subjects aged 5-19 years with DMD were included, nine in the control arm and 18 in the treatment arm to receive N-163 beta glucan along with conventional therapies for 45 days. While performing the analysis, patients were stratified into: those not administered steroids (Steroid -ve) (Control, n=5; treatment, n=9), those administered steroids (Steroid +ve) (Control, n=4; treatment, n=9), which was not pre-specified.Results IL-6 showed a significant decrease in the N-163 Steroid -ve group, from 7.2 ± 1.2 pg/ml to ± 0.03 pg/ml. IL-13 decreased in both treatment groups—from 157.76 ± 148.68 pg/ml to 114.08 ± 81.5 pg/ml (N-163 Steroid -ve) and from 289.56 ± 232.88 pg/ml to 255.56 ± 214.13 pg/ml (N-163 Steroid +ve). TGF-β levels showed a significant decrease in the N-163 Steroid –ve group. Dystrophin levels increased by up to 32% in both treatment groups. Medical research council (MRC) grading showed slight improvement in muscle strength improvement in 12 out of 18 patients (67%) in the treatment group and four out of nine (44%) subjects in the control group.Conclusion Supplementation with the N-163 beta glucan food supplement produced beneficial effects: a significant decrease in inflammation and fibrosis markers, increase in serum dystrophin and slight improvement in muscle strength in DMD subjects over 45 days, thus making this a potential adjunct treatment for DMD after validation.Trial registration The study was registered in Clinical trials registry of India, CTRI/2021/05/033346. Registered on 5th May, 2021.Competing Interest StatementAuthor Samuel Abraham is a shareholder in GN Corporation, Japan which in turn is a shareholder in the manufacturing company of the Beta Glucans described in the study.Clinical TrialClinical trials registry of India, CTRI/2021/05/033346Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Ethics Committee (IEC) of Saravana Multispeciality Hospital, India on 12th April, 2021.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscriptDMDDuchenne muscular dystrophyCKCreatinine kinaseTNF-αtumour necrosis factor – AlphaMRCMedical research councilNLRNeutrophil-to-lymphocyte ratioLCRLymphocyte-to-CRP ratioLeCRLeukocyte-to-CRP ratioNASHNon-alcoholic steatohepatitis6MWTSix-minute walk testNSAANorth Star Ambulatory AssessmentLGMDLimb girdle muscular dystrophy